AUTHORS
Ruth Sikora, Dr., Tabea Fröhlich, Dr.2, Regina Isemann, MD3, Natalie Petruch, MD4, Carina Scheer, MD5, Annamaria Brioli6, Florian H. Heidel IV, MD7, Christian R. Schultze-Florey, PD Dr.8
AFFILIATIONS
1 Hannover Medical School, Hannover, Lower-Saxony, Germany
2 Hannover Medical School, Hannover, Lower-Saxony, Germany, Hannover Medical School, Hannover, Lower-Saxony, Germany
3 Hannover Medical School, Hannover, Lower-Saxony, Germany
4 Hannover Medical School, Hannover, Lower-Saxony, Germany
5 Hannover Medical School, Hannover, Lower-Saxony, Germany
6 Hannover Medical School, Hannover, Lower-Saxony, Germany
7 Hannover Medical School, Hannover, Lower-Saxony, Germany
8 Hannover Medical School, Hannover, Lower-Saxony, Germany
ABSTRACT
Introduction: Large B-cell lymphoma (LBCL) is an aggressive and highly proliferative disease in which rapid disease control is essential, particularly in patients with relapsed or refractory (r/r) disease. This is especially pronounced in patients requiring bridging treatment before CAR-T cell therapy. Glofitamab, a CD20×CD3 bispecific antibody, has demonstrated efficacy in combination with gemcitabine and oxaliplatin (GemOx) (Abramson et al. 2024). The approved dosing schedule requires gradual Glofitamab dose escalation before administration of the first full dose, 21 days post treatment initiation. An accelerated Glofitamab step-up schedule, reaching the full dose by cycle 1 day (C1D) 8, has previously been shown to be safe and feasible as monotherapy (Cartron et al. 2025, Amisha et al. 2026). However, whether this can also be safely applied in combination with GemOx has not been studied systematically, as a recent report contained various Glofitamab treatment regimens with different step-up dosing plans (Liem et al 2026). Therefore, we tested the established accelerated step-up schedule in combination with GemOx only, to achieve earlier full-dose Glofitamab exposure and reduction of hospitalization.
Methods: We retrospectively analyzed 10 patients with CD20-positive r/r LBCL treated at Hannover Medical School between November 2025 and May 2026. LBCL subtypes included diffuse large B-cell lymphoma (n=9) and post-transplant lymphoproliferative disorder (n=1). Patients received obinutuzumab on C1D-3, followed by GemOx on C1D-2. Glofitamab was administered on C1D1 (2.5 mg), C1D3 (10 mg), and C1D8 (30 mg). Glofitamab step-up doses were only applied when the patient was free of Cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) for a minimum of 24 hours. Treatment cycles were repeated every 21 days. The primary objective was to evaluate the safety and feasibility of accelerated Glofitamab step-up in combination with GemOx.
Results: Median age was 72 years (range, 20–83); 70% of patients were male. Patients represented a clinically high-risk cohort: 8 (80%) had an International Prognostic Index (IPI) of ≥3, 3 (30%) had primary refractory disease and 6 (60%) had experienced early relapse following first line therapy. Eight patients (80%) received treatment as bridging before CAR-T cell therapy. No patient had received prior CAR-T or bispecific antibody therapy.
CRS occurred in 7 patients (70%), including grade 1 in 3 patients, grade 2 in 3 patients, and one grade 3. In 5/7 patients CRS occurred following the first Glofitamab administration. CRS was treated in 4/7 patients with a median of 1 dose of tocilizumab. Only one patient with CRS grade 3 received 3 doses dexamethasone until CRS resolved completely. C1D8 was postponed in 7/10 patient for a median of 1 day (range 1-2) due to CRS. No ICANS were observed.
Hematologic toxicities were common. Neutropenia occurred in 6 patients, including grade ≥3 neutropenia in 3 (30%). Thrombocytopenia occurred in all patients, including grade 2 events in 2 patients and grade 3 events in 3 patients. New onset or aggravation of pre-existing peripheral neuropathy occurred in 5 patients (grade 1, n=4; grade 2, n=1), resulting in omission of oxaliplatin during subsequent cycles in 4 patients. Gemcitabine was discontinued in one patient from cycle 3 onwards due to treatment-related polyneuropathy. Transient grade ≥2 elevations of liver enzymes were observed in all patients (AST 10/10, ALT 9/10, gGT 7/10) all without clinical significance. Acute kidney injury (AKIN) occurred in 3 patients (grade 1); one case occurred immediately following obinutuzumab. One patient developed pneumonia requiring hospitalization after the third cycle; no other clinically relevant infections were observed.
Conclusions: Our accelerated Glofitamab/GemOx regimen was feasible and demonstrated a manageable safety profile in a high-risk cohort of patients with r/r LBCL. Toxicities, especially CRS and ICANS, were consistent with the published safety profile of Glofitamab/GemOx, despite earlier achievement of full-dose bispecific antibody exposure. The duration of treatment and consequently the length of hospital stay in cycle 1 was reduced by 10 days compared to a model patient without signs of CRS and/or ICANS treated with the standard regimen. These findings support short ramp-up Glofitamab/GemOx as a safe and feasibly strategy for patients requiring rapid disease control.
DISCLOSURES
Ruth Sikora, Dr.: Bristol Myers Squibb - Honoraria